TheraRadar
Data updated: May 26, 2026

XIMINO (minocycline hydrochloride)

Dermatology Approved 2012-07-11
1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Discontinued
First Approved
2012-07-11
Patent Cliff
2027

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: MINOCYCLINE HYDROCHLORIDE

XIMINO Approval History

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
15 FDA actions from 2012 to 2026
Jan 2026 SUPPL
Label · Labeling
Aug 2015 SUPPL
Mfg · Manufacturing (CMC)
Jul 2012 ORIGINAL
New Form · Type 3 - New Dosage Form

What XIMINO Treats

1 FDA approvals

Originally approved for its first indication in 2012 .

  • Other (1)
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT06246396 IRB202301939 2R01HL132448-05A1 Ph 4 recruiting Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
NCT05826912 APT-TBI-01 APT-TBI-01 Ph 2 enrolling by invitation Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
NCT02203552 results posted OSU-13165 NCI-2014-00851 Ph 2 completed Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
NCT02297412 results posted RU221408I NCI-2016-01592, RU221408I Ph 2 completed Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
NCT04076098 RP139-02/18 Ph 4 completed Locally Delivered Minocycline in Advanced Periodontitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XIMINO FDA Label Details

View full patent landscape →
3 OB patents · 3 families · 32 international docs across 11 countries

XIMINO Patents & Exclusivity

Latest Patent: Apr 2027

Patents (3 active)

US7541347 Expires Apr 2, 2027
US7544373 Expires Apr 2, 2027
US7919483 Expires Mar 7, 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for XIMINO

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2027
  • 45 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.